ReviewMolecular and cellular biochemistry2025
The gut microbiota-NLRP3 inflammasome connection: current evidence and perspectives for non-communicable diseases.
Review in Molecular and cellular biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Ganaxolone as a promising therapeutic agent for Alzheimer's disease: signaling pathways and mechanistic insights-a narrative review.Inflammopharmacology · 2026Review
- Rethinking the Diabetes-Cardiovascular Disease Continuum: Toward Integrated Care.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammasomes are cytoplasmic multiprotein complexes belonging to the innate immune system, playing a crucial role in responses to microbial infections and controlling mucosal immune responses and metabolic activities. The Nod-Like Pyrin Receptor Domain 3 (NLRP3) inflammasome is one of the most studied and may be a key element in the relationship between gut microbiota and systemic inflammation. Chronic non-communicable diseases have been closely associated with alterations in the gut microbiota (dysbiosis) and the activation of the inflammasome complex. Dysbiosis can expose the host to pathogenic microorganisms and their metabolites, thus triggering immune and inflammatory responses. This review discusses the importance of addressing the interaction between the gut microbiota and the NLRP3 inflammasome pathway and its possible effects on human health. Modulation of the intestinal microbiota may be a crucial factor in preventing and mitigating inflammation, and the NLRP3 inflammasome pathway appears to be substantially involved in this process.
Indexed as
Identifiers
40754620What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.